Valbiotis SA (FR:ALVAL)
:ALVAL
Want to see FR:ALVAL full AI Analyst Report?
Top Page
Valbiotis SA
(ALVAL)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.89
▲(23.33% Upside)
Action:Reiterated
Date:06/10/26
The score is constrained primarily by weak financial performance—persistent losses, negative gross profit in recent years, and ongoing cash burn that increases funding/dilution risk. Technicals add further pressure with the stock trading below key short-to-medium moving averages and momentum indicators in bearish/oversold territory. Valuation contributes only modestly given the negative P/E and lack of dividend yield data.
Positive Factors
Market focus & scientific positioning
Valbiotis targets durable consumer-health markets (dyslipidemia, prediabetes, hypertension) with science-backed, plant-based nutraceutical formulations. This strategic focus aligns with long-term demographic and chronic-disease trends and supports repeatable retail and partner revenue streams.
Negative Factors
Sustained unprofitability
Persistent large operating and net losses with negative gross profit indicate the business is not yet economically viable at current scale. This structural lack of profitability limits reinvestment, stresses margins, and requires either significant scale, cost restructuring, or margin expansion to reach self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Market focus & scientific positioning
Valbiotis targets durable consumer-health markets (dyslipidemia, prediabetes, hypertension) with science-backed, plant-based nutraceutical formulations. This strategic focus aligns with long-term demographic and chronic-disease trends and supports repeatable retail and partner revenue streams.
Read all positive factors
Valbiotis SA (ALVAL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€31.56M
Dividend YieldN/A
Average Volume (3M)112.19K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth417.14%
EPS Growth22.08%
CountryFR
Employees44
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,547,350
10 Day Avg. Volume162,174
30 Day Avg. Volume112,190
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)€3.63M
Valbiotis SA Business Overview & Revenue Model
Company Description
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular disea...
How the Company Makes Money
Valbiotis makes money primarily through the commercialization of its nutraceutical/dietary supplement products (consumer health products), generating revenue from product sales through distribution channels (e.g., retail/pharmacies and e-commerce,...
Valbiotis SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 905.00K | 175.00K | 4.73M | 785.00K | 298.00K |
| Gross Profit | -1.17M | -2.44M | 2.69M | 767.00K | 282.00K |
| EBITDA | -9.28M | -9.17M | -6.41M | -11.13M | -9.14M |
| Net Income | -9.42M | -10.03M | -7.37M | -12.31M | -8.68M |
Balance Sheet | |||||
| Total Assets | 14.39M | 19.61M | 33.31M | 27.17M | 28.48M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 11.58M | 25.02M | 20.83M | 21.82M |
| Total Debt | 5.09M | 5.72M | 6.88M | 7.18M | 7.59M |
| Total Liabilities | 7.43M | 9.24M | 13.71M | 13.86M | 14.25M |
| Stockholders Equity | 6.96M | 10.37M | 19.60M | 13.31M | 14.23M |
Cash Flow | |||||
| Free Cash Flow | -8.19M | -11.80M | -8.30M | -9.48M | -7.58M |
| Operating Cash Flow | -8.04M | -11.54M | -8.06M | -9.19M | -7.16M |
| Investing Cash Flow | -77.00K | -61.00K | -250.00K | -197.00K | -7.00K |
| Financing Cash Flow | 5.21M | -1.84M | 12.49M | 8.40M | 14.40M |
Valbiotis SA Technical Analysis
Negative
0.72
Price Trends
1.00
Negative
1.01
Negative
0.86
Positive
Market Momentum
-0.04
Positive
37.30
Neutral
19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.00, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 37.30 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALVAL.
Valbiotis SA Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | €6.77M | 11.84 | ― | ― | -40.95% | -39.70% | |
46 Neutral | €10.74M | -0.75 | ― | ― | 249.95% | 33.78% | |
46 Neutral | €57.32M | -5.56 | -33.26% | ― | 16.41% | 44.74% | |
45 Neutral | €517.91M | -6.02 | -63.70% | ― | -2.34% | -5574.92% | |
45 Neutral | €718.15M | -5.47 | ― | ― | -51.26% | 17.63% | |
42 Neutral | €31.56M | -2.23 | ― | ― | 417.14% | 22.08% |
* Consumer Defensive Sector Average
FR:ALVAL
Valbiotis SA
0.89
0.03
3.14%
FR:GNFT
Genfit
10.38
6.99
206.01%
FR:IVA
Inventiva
3.04
0.26
9.35%
FR:POXEL
Poxel SA
0.20
-0.41
-67.32%
FR:ALGAE
Fermentalg SA
0.48
-0.01
-2.05%
FR:ALPAT
Plant Advanced Technologies SA
6.00
-4.20
-41.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.